title: [Ibudilast prevents oligodendroglial excitotoxicity].
abstract: Previously we have demonstrated that cells of oligodendroglial lineage express non-N-methyl-D-aspartate (NMDA) glutamate receptor (GluR) genes and are damaged by kainate induced Ca2+ influx via non NMDA GluR channels of the alpha-amino-3-hydroxy-5-methyl 4 isoxazole propionate (AMPA) type, representing oligodendroglial excitotoxicity. We here present the finding that ibudilast, which is used clinically for treat patients with asthma and cerebrovascular diseases, prevents oligodendroglia excitotoxicity. The oligodendrocyte like cells (OLC), differentiated from the CG-4 cell line established from rat oligodendrocyte-type 2 astrocyte (O-2A) progenitor cells, were exposed to 2 mM kainate for 24 h and cell death was evaluated by measuring activity of lactate dehydrogenase (LDH) released into the culture medium. Kainate induced cell death was prevented by 10 to 100 microM ibudilast, which increased intracellular cAMP. A 45Ca2+ influx study revealed that ibudilast attenuated kainate-induced Ca2+ influx. Inhibition of kainate-induced Ca2+ influx by ibudilast was decreased by H-89, a protein kinase A (PKA) inhibitor, but increased by okadaic acid, an inhibitor of phosphatase 1 and 2A. Therefore, we concluded that ibudilast prevented oligodendroglial excitotoxicity by a PKA-dependent phosphorylation process resulting in decreased kainate-induced Ca2+ influx.
authors.affiliation: Department of Neurology, Kanazawa Medical University, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Yoshioka
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
authors.forename: G
authors.initials: G
authors.lastname: Hirose
mesh_terms: D000818:Animals; D001993:Bronchodilator Agents / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D016923:Cell Death; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000032:analysis; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018846:Excitatory Amino Acids / Q000378:metabolism*; D007546:Isoquinolines / Q000494:pharmacology; D007608:Kainic Acid / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D019319:Okadaic Acid / Q000494:pharmacology; D009836:Oligodendroglia / Q000187:drug effects*; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D013449:Sulfonamides; D014665:Vasodilator Agents / Q000494:pharmacology*; D007212:Indolizines; D011720:Pyrazoles
chemical_list: D001993:Bronchodilator Agents; D002118:Calcium; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D018846:Excitatory Amino Acids; D007546:Isoquinolines; D007608:Kainic Acid; D007770:L-Lactate Dehydrogenase; D019319:Okadaic Acid; D011725:Pyridines; D013449:Sulfonamides; D014665:Vasodilator Agents; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide